← back to search

Megan L. Stanifer

University of Florida · US
Area of research
Infectious Diseases · Immunology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, interferon and immune responses, Viral gastroenteritis research and epidemiology, and COVID-19 Clinical Research Studies.
h-index
36
citations
6,442
works
113
NIH funding
primary concept
email

Recent publications

The population context is a driver of the heterogeneous response of epithelial cells to interferons
Molecular Systems Biology 2024cited by 3position: middledoi
Transcriptomics-inferred dynamics of SARS-CoV-2 interactions with host epithelial cells
Science Signaling 2023cited by 5position: middledoi
Extended methods for spatial cell classification with DBSCAN-CellX
Scientific Reports 2023cited by 4position: middledoi
Influence of cell type specific infectivity and tissue composition on SARS-CoV-2 infection dynamics within human airway epithelium
PLoS Computational Biology 2023cited by 2position: middledoi
Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries
Nature Genetics 2022cited by 136position: middledoi
A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells
Cell Metabolism 2022cited by 112position: middledoi
A family of conserved bacterial virulence factors dampens interferon responses by blocking calcium signaling
Cell 2022cited by 67position: middledoi
The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication <i>In Vitro</i> and Decreases Viral Titers and Disease Progression in Syrian Hamsters
mBio 2022cited by 41position: middledoi
Type III and Not Type I Interferons Efficiently Prevent the Spread of Rotavirus in Human Intestinal Epithelial Cells
Journal of Virology 2022cited by 33position: middledoi
Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells
Journal of Virology 2022cited by 32position: middledoi
USP22 controls type III interferon signaling and SARS-CoV-2 infection through activation of STING
Cell Death and Disease 2022cited by 27position: middledoi
A model for network-based identification and pharmacological targeting of aberrant, replication-permissive transcriptional programs induced by viral infection
Communications Biology 2022cited by 8position: middledoi
USP22 controls type III interferon signaling and SARS-CoV-2 infection through activation of STING
bioRxiv (Cold Spring Harbor Laboratory) 2022cited by 3position: middledoi
Protocol for SARS-CoV-2 infection of kidney organoids derived from human pluripotent stem cells
STAR Protocols 2022cited by 2position: middledoi
A Model for Network-Based Identification and Pharmacological Targeting of Aberrant, Replication-Permissive Transcriptional Programs Induced by Viral Infection
Research Square 2022cited by 0position: middledoi
TMPRSS2 expression dictates the entry route used by SARS‐CoV‐2 to infect host cells
The EMBO Journal 2021cited by 368position: middledoi
Single‐cell analyses reveal SARS‐CoV‐2 interference with intrinsic immune response in the human gut
Molecular Systems Biology 2021cited by 118position: lastdoi
Single‐cell transcriptomics reveals immune response of intestinal cell types to viral infection
Molecular Systems Biology 2021cited by 57position: middledoi
SARS‐CoV‐2 infection remodels the host protein thermal stability landscape
Molecular Systems Biology 2021cited by 37position: middledoi
Functional comparison of MERS-coronavirus lineages reveals increased replicative fitness of the recombinant lineage 5
Nature Communications 2021cited by 34position: middledoi
Genetic regulation of <i>OAS1</i> nonsense-mediated decay underlies association with risk of severe COVID-19
medRxiv 2021cited by 12position: middledoi
Conserved Induction of Distinct Antiviral Signalling Kinetics by Primate Interferon Lambda 4 Proteins
Frontiers in Immunology 2021cited by 8position: middledoi
The endogenous cellular protease inhibitor SPINT2 controls SARS-CoV-2 viral infection and is associated to disease severity
PLoS Pathogens 2021cited by 8position: middledoi
Adapting Gastrointestinal Organoids for Pathogen Infection and Single Cell Sequencing under Biosafety Level 3 (BSL-3) Conditions
Journal of Visualized Experiments 2021cited by 2position: firstdoi
Dynamics of SARS-CoV-2 host cell interactions inferred from transcriptome analyses
bioRxiv (Cold Spring Harbor Laboratory) 2021cited by 2position: middledoi
A diabetic <i>milieu</i> increases cellular susceptibility to SARS-CoV-2 infections in engineered human kidney organoids and diabetic patients
bioRxiv (Cold Spring Harbor Laboratory) 2021cited by 2position: middledoi
Increased sensitivity of SARS-CoV-2 to type III interferon in human intestinal epithelial cells
bioRxiv (Cold Spring Harbor Laboratory) 2021cited by 0position: middledoi
Network-based identification and pharmacological targeting of host cell master regulators induced by SARS-CoV-2 infection
bioRxiv (Cold Spring Harbor Laboratory) 2021cited by 0position: middledoi
Conserved induction of distinct antiviral signalling kinetics by primate interferon lambda 4 proteins
bioRxiv (Cold Spring Harbor Laboratory) 2021cited by 0position: middledoi
Adapting Gastrointestinal Organoids for Pathogen Infection and Single Cell Sequencing under Biosafety Level 3 (BSL-3) Conditions
Journal of Visualized Experiments 2021cited by 0position: firstdoi

Grants

Role of type III interferons in promoting barrier formation at mucosal surfaces
NSF2528816$1,261,5462025–2029PIRePORTER

Frequent collaborators

Steeve Boulant · University of Florida61 papers (2013–2024)Patricio Doldan · Queen Mary University of London13 papers (2020–2024)Carmon Kee · Heidelberg University12 papers (2020–2022)Sergio Triana · Broad Institute9 papers (2020–2022)Theodore Alexandrov · BioInnovation Institute9 papers (2020–2022)Kalliopi Pervolaraki · KU Leuven7 papers (2017–2019)Dorothee Albrecht · German Cancer Research Center7 papers (2017–2019)Camila Metz‐Zumaran · German Cancer Research Center7 papers (2021–2024)Markus Mukenhirn · University of Cambridge6 papers (2018–2021)Cuncai Guo · Heidelberg University6 papers (2019–2022)Ralf Bartenschlager · German Cancer Research Center5 papers (2016–2021)Thomas Hielscher · German Cancer Research Center4 papers (2018–2019)Stephanie Muenchau · University Hospital Heidelberg4 papers (2018–2019)Pierre‐Yves Lozach · Université Claude Bernard Lyon 14 papers (2015–2021)Juan L. Mendoza · Howard Hughes Medical Institute4 papers (2018–2020)Thomas Höfer · Roche (Switzerland)4 papers (2018–2024) · 4 papers (2018–2021)Soheil Rastgou Talemi · Harvard University4 papers (2018–2024)Mohammed Shahraz · European Bioinformatics Institute4 papers (2020–2021)John McLauchlan · University of Glasgow4 papers (2018–2021)